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1
The pharmaceutical industry is facing an era of 
fundamental transformation, with new products, 
markets, and regulations requiring changes to 
governance, risk and supply chain management. 
These represent both threats and opportunities 
to the industry, for those who are able to harness 
developments. 
Through the provision of example scenarios, this 
report aims to provide pharmaceutical supply chain 
managers with the necessary information to help them 
find the right strategic solutions for their companies 
over the next ten years. 
Based on a thorough review of current practical and 
academic literature, the research team identified 
twelve future key developments with the potential to 
impact pharmaceutical supply chains over the next 
ten years (2015-2025). Based on assessments by 
30 European pharmaceutical managers, the report 
provides analysis of the probability and impact of 
each development on pharmaceutical supply chains. 
It scopes the extent to which pharmaceutical supply 
chain managers welcome and feel able to influence 
each development.
The study finds that developing robust compliance and 
risk management measures ranks as the most likely 
development that will have the greatest impact on the 
industry. Expanding into emerging markets and the 
availability of detailed patient data to increase efficacy 
through precise forecasting are also predicted to have 
a significant impact on the industry. 
The research team clustered the results from the 
consultation with expert managers to provide a future 
map of pharma supply chains. This map enables 
companies to think about how to build strategies to 
adapt to the forecasted challenges early on. 
In order to enable managers to really visualise the 
future, and plan accordingly, the research team builds 
four different scenarios using two of the predicted 
challenges (complexity and uncertainty) providing 
analysis and strategy recommendations for each 
scenario. 
The report concludes with a short overview of the 
key challenges facing pharma and suggests some 
strategies that will enable companies to not only deal 
with these challenges, but lead the industry.  
1 Executive summary
The study finds that developing robust 
compliance and risk management measures 
ranks as the most likely development, and 
the one that will have the greatest impact on 
the industry
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